Nontuberculous mycobacterial pulmonary diseases (NTMPDs) are a group of infectious diseases caused by various species of mycobacteria other than Mycobacterium tuberculosis. These pathogens are most commonly found in the environment and can cause lung infections in immunocompromised individuals or those without obvious risk factors. The most common pathogens in this group include Mycobacterium avium complex, Mycobacterium abscessus, and Mycobacterium kansasii. Symptoms of NTMPD can range from mild discomfort to severe respiratory distress, including cough, night sweats, weight loss, and difficulty breathing. Because the disease can be difficult to diagnose and requires prolonged treatment, its public health importance is of increasing importance.
History of the disease and interesting historical facts
The history of non-tuberculous mycobacterial diseases goes back to the 20th century, although the first mentions of mycobacteria date back to the 19th century. In 1882, German bacteriologist Robert Koch discovered the causative agent of tuberculosis, but at that time, attention to other types of mycobacteria was minimal. The first cases of diseases caused by Mycobacterium avium and other non-tuberculous mycobacteria began to be described only in the 1930s, and real epidemiological studies on these reasons began later, in the 1950s and 1960s. At that time, researchers noticed a connection between these infections and conditions associated with a weakened immune system, especially in HIV-infected patients. An interesting fact is that in modern conditions, non-tuberculous mycobacterial infections have become more common, especially in countries with high levels of tuberculosis, which requires a revision of approaches to the diagnosis and treatment of these diseases.
Epidemiology
The epidemiology of nontuberculous mycobacterial lung diseases shows that they are increasingly common. According to the Centers for Disease Control and Prevention (CDC), the number of reported cases of NMZL in the United States has increased by approximately 5-10% per year over the past two decades. Studies have shown that the incidence is at the level of 1.5-2 per 100,000 population in the general population, while in the elderly this rate is much higher, reaching 8-15 cases per 100,000. The gender ratio is also important: women suffer more often from these diseases, especially in middle age. Geographically, the diseases are more common in certain regions, such as the southern and southeastern states of the United States, where there is high humidity and high temperatures, which contribute to the proliferation of mycobacteria.
Genetic predisposition to this disease
Genetic predisposition to non-tuberculous mycobacterial lung diseases has been studied for the past decades. It has been established that the presence of certain polymorphisms in genes responsible for the immune response (such as TNF, IL-10, IFN-γ) can increase the likelihood of the disease. In particular, polymorphisms in the TNF-α gene are associated with an increased risk of developing infections in people with weakened immunity. Scientists have also paid attention to mutations in genes responsible for the activation of macrophages, which play a key role in the immune defense response. For example, mutations in the IRF5 gene can affect the body's ability to respond to mycobacteria. During studies, it was observed that patients with hereditary immunodeficiencies or certain autoimmune diseases have a significantly higher risk of developing NMSL.
Risk factors for the development of this disease
Risk factors contributing to the development of non-tuberculous mycobacterial lung diseases include both physical and chemical exposures. The main risks can be classified as follows:
- Immunodeficiency: HIV infection, hematological diseases, long-term therapy with immunosuppressants.
- Chronic lung diseases: COPD, asthma, cystic fibrosis, bronchiectasis.
- Age: Older patients (usually over 65 years of age) are at greater risk.
- Smoking and alcohol: Both of these factors significantly reduce immune function and contribute to the development of lung diseases.
- Environmental Impact: Living in high humidity and poor sanitation conditions increases the risk.
Additionally, certain occupations involving work in agriculture, construction, and water supply exhibit increased risk due to potential exposure to mycobacteria in soil or water.
Diagnosis of this disease
Diagnosis of non-tuberculous mycobacterial lung diseases includes several important stages. The main symptoms of the disease may be non-specific and include:
- Long-term cough, often productive.
- Shortness of breath and difficulty breathing.
- Night sweats.
- Weight loss.
- Fatigue and general weakness.
Laboratory tests usually include infectious testing for mycobacteria. The main method is bronchoscopy with biopsy and subsequent microscopic examination for the presence of mycobacteria. PCR (polymerase chain reaction) is also an effective method in diagnosis. Radiological examinations, such as chest X-ray or CT scan, help to identify characteristic changes in lung tissue, including the following:
- Diverticular changes.
- Infiltrative changes.
- Bronchiectasis.
Other diagnostics may include serologic tests and physical examination. The differential diagnosis must exclude tuberculosis, pneumonia, lung tumors, and other lung diseases to properly administer treatment.
Treatment
Treatment of non-tuberculous mycobacterial lung diseases requires a comprehensive and often long-term approach. General treatment includes both pharmacological methods and non-drug interventions:
- Pharmacological treatment: Antibiotics such as azithromycin and rifampin are used.
- Surgery: May be necessary in severe cases, especially with widespread bronchiectasis or abscess formation.
- Other treatments include breathing exercises, physical therapy and, in some cases, immunotherapy.
Treatment may last from several months to several years, depending on the specific infection and the patient's response to therapy.
List of medications used to treat this disease
The list of drugs used to treat non-tuberculous mycobacterial lung diseases may include:
- Azithromycin
- Rifampicin
- Clarithromycin
- Ethambutol
- Synoclav (Clofazimine)
Each of these drugs may be prescribed depending on the sensitivity of the specific pathogen and the patient's condition.
Disease monitoring
Monitoring the condition of a patient with non-tuberculous mycobacterial lung diseases includes regular checks and assessment of the dynamics of the disease. The main control stages may include:
- Regular chest X-rays.
- Monitoring laboratory values (eg, blood tests for inflammation).
- Assessment of the patient's symptoms and general condition.
The prognosis depends on the timeliness of diagnosis and treatment, as well as the presence of concomitant diseases. Complications may include progression of pulmonary dysfunction and development of bronchiectasis.
Age-related features of the disease
Age-related features of non-tuberculous mycobacterial lung diseases are noted depending on the age group. In young people, the disease is less common, but may be accompanied by a more aggressive course. In elderly patients, the disease is often diagnosed later, which causes a more severe clinical course and concomitant comorbid conditions. At the age of 60 years and older, the risk of complications increases significantly, which requires a more careful approach to diagnosis and treatment.
Questions and Answers
- What are the main symptoms of non-tuberculous mycobacterial lung disease? The main symptoms include long-term cough, shortness of breath, night sweats, weight loss and general weakness.
- How is this disease diagnosed? Diagnosis includes laboratory tests, radiological examinations, and differential diagnosis to exclude other lung diseases.
- What treatment is used for non-tuberculous mycobacterial diseases? Treatment includes antibiotics, possible surgery, and other medical procedures.
- What are the risk factors for developing the disease? Risk factors include immunodeficiencies, chronic lung disease, smoking, age over 65 years, and occupational exposure.
- What is the prognosis for this disease? The prognosis depends on the time of initiation of treatment and the presence of comorbidities; in severe cases, complications such as pulmonary dysfunction may occur.
